表紙
市場調査レポート

癌サイトカイン治療薬のパイプライン分析

Cancer Cytokines Therapy Pipeline Analysis

発行 PNS Pharma 商品コード 308690
出版日 ページ情報 英文 231 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌サイトカイン治療薬のパイプライン分析 Cancer Cytokines Therapy Pipeline Analysis
出版日: 2014年06月01日 ページ情報: 英文 231 Pages
概要

癌サイトカイン市場の成長は主に、研究開発費の増加に伴う癌療法向けアプリケーションの増加、技術の進歩、特許の期限切れ、および競合の激化によって促進されています。今後4-5年にわたって、製薬企業はサイトカインをベースにした癌療法の開発に更に重点的に取り組むと予測されています。

当レポートでは、癌サイトカイン療法市場について調査し、市場概要、上市薬のプロファイル・特許分析、フェーズ・国別の治験分析、臨床開発段階の薬剤、前臨床段階において多数を占める療法、上市済みサイトカイン療法、治験が停止・中止された薬剤のプロファイルおよび競合情勢などをまとめ、お届けいたします。

第1章 癌サイトカイン療法市場の概要

第2章 癌サイトカイン療法の治験分析:フェーズ・国・標的適応症

  • 未確認段階
  • 研究
  • 前臨床
  • 臨床
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズIII

第3章 上市済み癌サイトカイン臨床プロファイル・特許分析

第4章 治験において停止・中止された癌サイトカイン療法

  • 未開発
  • 中止
  • 停止

第5章 競合情勢

  • Altor BioScience
  • Biogenomics
  • Biosidus
  • Chiron Corporation (Novartis)
  • Expression Genetics
  • IRX Therapeutics
  • Philogen
  • Roche
  • Regulon
  • ZymoGenetics

図表リスト

目次

Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capability to stop tumor growth. Cytokines are considered to be a large, diverse group of extracellular proteins which are produced by the immune system cells. These cytokines have the capacity to be bound by the cytokine receptors on the targeted cells. This process initiates a signaling cascade within those cells.

The growth in the cytokines market is mainly driven by its increased application for cancer treating methods, along with an increased spending on research and development, advances in technology, patent expiries, and rising competition. Cytokines are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies, proteins and nucleic acid probes which are being extensively used in a wide variety of applications from the basic research laboratory through the drug discovery process, to in vivo therapeutic use. The companies producing these proteins are focusing their strategy on offering high quality products at more than competitive prices.

It is expected that in the next 4-5 years, the pharma companies would focus more on the development of successful cancer therapies based on cytokines. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new cytokines products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. This segment has proved to be the most important investment to control the sprawling rise in cancer incidence rates. Also, from a commercial viewpoint, these cytokine products are likely to churn significant revenues and for the patient population, and eventually are expected to improve the survival rates and improve quality of life.

“Cancer Cytokines Therapy Pipeline Analysis” Report Highlights:

  • Cancer Cytokines Therapy Market Overview
  • Marketed Drug Profiles & Patent Analysis
  • Clinical Trial Insight by Phase & Country
  • Drug in Clinical Development Phase: 64
  • Majority Therapies in Preclinical Phase: 25
  • Marketed Cytokines Therapies: 15
  • Suspended & Discontinued Drug Profiles: 67
  • Competitive Landscape

Table of Contents

1. Cancer Cytokines Therapy Market Overview

  • 1.1. Market Overview
  • 1.2. Clinical Pipeline Insight

2. Cancer Cytokine Therapy Clinical Trial Insight by Phase, Country & Target Indications

  • 2.1. Unknown Phase
  • 2.2. Research
  • 2.3. Preclinical
  • 2.4. Clinical
  • 2.5. Phase I
  • 2.6. Phase I/II
  • 2.7. Phase II
  • 2.8. Phase III

3. Marketed Cancer Cytokines Clinical Profile & Patent Analysis

4. Suspended & Discontinued Cancer Cytokines Therapy in Clinical Trial

  • 4.1. No Development Reported
  • 4.2. Discontinued
  • 4.3. Suspended

5. Competitive Landscape

  • 5.1. Altor BioScience
  • 5.2. Biogenomics
  • 5.3. Biosidus
  • 5.4. Chiron Corporation (Novartis)
  • 5.5. Expression Genetics
  • 5.6. IRX Therapeutics
  • 5.7. Philogen
  • 5.8. Roche
  • 5.9. Regulon
  • 5.10. ZymoGenetics
  • Figure 1-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-3: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-4: No Development in Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-5: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-6: Discontinued Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 1-7: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 1-8: Suspended Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 5-1: Expression Genetics Clinical Pipeline
  • Figure 5-2: Philogen Clinical Pipeline

List of Tables

Following Information For Each Drug Profile in Covered in More than 200 Tables in Report:

  • Drug Profile Overview
  • Active Indication
  • Phase of Development
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
Back to Top